Infinity Pharmaceuticals, Inc.

OTCPK:INFI.Q 株式レポート

時価総額:US$90.0

Infinity Pharmaceuticals マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Seth Tasker

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間7.7yrs
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間6yrs

経営陣の近況

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18
Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15
Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11
Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

CEO報酬分析

Infinity Pharmaceuticals の収益と比較して、Seth Tasker の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$43m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021n/an/a

-US$45m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$1mUS$386k

-US$40m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$653kUS$368k

-US$47m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018n/an/a

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$41m

Dec 31 2017US$1mUS$320k

-US$42m

報酬と市場: Sethの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Sethの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Seth Tasker (44 yo)

7.7yrs

在職期間

US$1,435,444

報酬

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...


取締役

名称ポジション在職期間報酬所有権
Anthony Evnin
Independent Director17.5yrsUS$93.08k0.24%
$ 0.2
Norman Selby
Lead Independent Director12yrsUS$125.82k0.017%
$ 0.01
David Beier
Independent Director5.9yrsUS$85.58k0.0097%
$ 0.009
Roy Steven Herbst
Member of Scientific Advisory Board6yrsデータなしデータなし
David Munn
Member of Scientific Advisory Board6yrsデータなしデータなし
F. Hodi
Member of Scientific Advisory Board6yrsデータなしデータなし
Richard B. Gaynor
Independent Director4yrsUS$83.08k0%
$ 0
Dmitry Gabrilovich
Member of Scientific Advisory Board6yrsデータなしデータなし
Jeffery Kutok
Chairman of Scientific Advisory Board4yrsUS$759.67kデータなし
Samuel Agresta
Chair of Clinical Advisory Boardno dataUS$73.08k0.012%
$ 0.01
Toni Choueiri
Member of Clinical Advisory Boardno dataデータなしデータなし
Michael Postow
Member of Clinical Advisory Boardno dataデータなしデータなし

6.0yrs

平均在職期間

71yo

平均年齢

経験豊富なボード: INFI.Qの 取締役会経験豊富 であると考えられます ( 6年の平均在任期間)。